sameAs
Detectable clonal mosaicism and its relationship to aging and cancerImputation and subset based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33Characterization of large structural genetic mosaicism in human autosomeAnalysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer typesTGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancersPrognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature ReviewMolecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and diseaseA genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33Choline and betaine intake and the risk of colorectal cancer in menMolecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary fieldGenome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancerPhenotypic and tumor molecular characterization of colorectal cancer in relation to a susceptibility SMAD7 variant associated with survivalMultivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803Alcohol intake and pancreatic cancer risk: a pooled analysis of fourteen cohort studiesDietary choline and betaine and the risk of distal colorectal adenoma in womenAssociation of the TCF7L2 polymorphism with colorectal cancer and adenoma riskEtiologic field effect: reappraisal of the field effect concept in cancer predisposition and progressionHow many molecular subtypes? Implications of the unique tumor principle in personalized medicineAspirin and the risk of colorectal cancer in relation to the expression of COX-2.KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers.Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosomeAnorectal Cancer: Critical Anatomic and Staging Distinctions That Affect Use of Radiation TherapyA prospective study of aspirin use and the risk of pancreatic cancer in womenA prospective study of aspirin use and the risk for colorectal adenomaAPC Asp1822Val and Gly2502Ser polymorphisms and risk of colorectal cancer and adenomaLong-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancerLow plasma adiponectin levels and risk of colorectal cancer in men: a prospective studyAspirin, other NSAIDs, and ovarian cancer risk (United States)A prospective study of genetic polymorphisms in the cytochrome P-450 2C9 enzyme and the risk for distal colorectal adenomaGenetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenomaPlasma vitamin D metabolites and risk of colorectal cancer in womenLong-term aspirin use and mortality in womenAssessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectumAspirin use, tumor PIK3CA mutation, and colorectal-cancer survivalCDK8 is a colorectal cancer oncogene that regulates beta-catenin activityFusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironmentAspirin therapy for colorectal cancer with PIK3CA mutation: simply complex!TERT gene harbors multiple variants associated with pancreatic cancer susceptibilityPhysical activity and risk of inflammatory bowel disease: prospective study from the Nurses' Health Study cohorts
P50
Q23916196-785D74EA-C2C9-4662-8EBC-2231DE56AC48Q23924183-36FD3A04-A32D-439C-BCFE-7128D0A9D9A0Q24169697-80AA2757-185D-4771-B730-EEFCC5581471Q24170413-4E4AAFDC-B278-4898-9867-D4862AE0CC15Q24288715-79D2913C-BFBF-46F1-ACD3-0120A0C47754Q24289005-F9CAF27B-9BA7-4F13-811E-F81DAE676C8DQ24289344-5C6CD988-A1F2-4A37-996C-622B26D8207EQ24597370-D659462B-386A-4C75-ADBA-D6DCF36F80FCQ24598047-5CABA115-E5D8-4524-94B5-CB256FD3EA8FQ24620628-4D7ADBE3-B7B2-4C7B-98B2-553EEAA767DCQ24626464-DFAEA9DD-9311-4B00-BF71-480D4379FFD4Q24626799-89287837-2315-4DD4-94C3-0BF4ADE3ED20Q24632418-8C6D3699-F10C-445F-B512-36B5506EE490Q24644568-AB962F54-DB4B-46CE-9262-7A4BCCED7E21Q24649145-A280C9CD-0BE4-4C7D-BF1F-15692484F946Q24658332-DDFB92CF-4A89-4F11-9D96-E1EB40CF5DE4Q26852716-FF479778-583D-4191-8D16-3E1B553044C2Q26992045-D932420E-C307-47EA-9749-FC606BC5470BQ27851408-452AF1F9-D169-4CF7-B667-4C5452303078Q27851532-378C2EF6-4259-4A9A-939A-889539D56B9DQ27851557-0BC6A385-954A-45A5-858D-058C61FDC7F5Q27908479-1152EEBC-2B18-441B-A805-6903322FE8DDQ28082745-E403E63E-C2CE-44A1-AC70-2E79978E2A9BQ28166674-E76B16A7-94F6-4D5D-A22D-4316A8A93779Q28167060-708D0863-99FE-4912-BD1A-17812222E00AQ28174023-1FCF34DC-ECBB-4810-B41C-D7EB3CC96F98Q28188848-01712715-AC33-43EF-9A1A-58533C4662E3Q28193386-FE597888-AA52-4D67-AAE9-7EEEB10CF78AQ28193649-6072483F-674E-4886-9BEC-E08DC5A875AAQ28210138-D6689683-0E92-4801-9F4E-CA597F108AA3Q28210569-F120A7E7-DDDF-486D-B605-CA08ADE0101EQ28212172-ABE0EF18-A8B4-4C66-A960-480E5F6BC15FQ28221611-97CDB4C7-D649-40C7-AF63-F4AAACEA3ED3Q28262150-5D863083-ECB9-46F4-A0B5-F9817FA5121BQ28277824-371C1E69-EADA-48D7-9C36-0EF5BA34CD5BQ28294122-6E23195F-1682-4AF7-80CA-EC42DF818F19Q28296759-AA221515-DF40-4A2C-90C2-7FEFD714047EQ28301003-DD67718E-8C8D-4A0E-9883-2BB4AAB942C4Q28386653-C7D79C2A-F9CB-4BE9-AAFE-39DF3793A6EEQ28658603-75EFBC3B-2A68-4A34-919E-1A6AB351A8B2
P50
description
Director of the Yale Cancer Center
@en
name
Charles S. Fuchs
@de
Charles S. Fuchs
@en
Charles S. Fuchs
@es
Charles S. Fuchs
@fr
Charles S. Fuchs
@pt
type
label
Charles S. Fuchs
@de
Charles S. Fuchs
@en
Charles S. Fuchs
@es
Charles S. Fuchs
@fr
Charles S. Fuchs
@pt
altLabel
C Fuchs
@en
C S Fuchs
@en
C. Fuchs
@en
C. S. Fuchs
@en
Charles Fuchs
@en
Charles S Fuchs
@en
Fuchs C
@en
Fuchs C. S.
@en
Fuchs C.
@en
Fuchs CS
@en
prefLabel
Charles S. Fuchs
@de
Charles S. Fuchs
@en
Charles S. Fuchs
@es
Charles S. Fuchs
@fr
Charles S. Fuchs
@pt
P214
P106
P21
P214
P31
P496
0000-0003-1582-9842
P735
P7859
viaf-305708451